Novo Nordisk A/S (NYSE:NVO) reported positive topline results from its late-stage PIONEER TEENS trial, showing that oral semaglutide significantly improved blood sugar control in children and adolescents with type 2 diabetes.
Oral Semaglutide Shows Superior Glycaemic Control
The phase 3a study evaluated oral semaglutide in patients aged 10–17 years and found the drug delivered a superior reduction in HbA1c (blood sugar levels) compared to placebo.
The trial demonstrated a statistically significant and superior reduction in blood sugar by 0.83% versus placebo at 26 weeks.
The treatment also demonstrated a safety profile consistent with prior semaglutide trials, reinforcing its tolerability.
Oral semaglutide is currently marketed as Rybelsus in the U.S. and Europe.
Novo Nordisk expects to file for regulatory approval of a label expansion for Ozempic pill and Rybelsus in the U.S. and EU in the second half of the year.
Rising Burden Of Youth-Onset Type 2 Diabetes
The prevalence of type 2 diabetes among children and adolescents has increased significantly over the past two decades, creating a substantial unmet medical need. The condition is associated with higher risks of early mortality later in life.
Globally, an estimated 14.6 million adolescents were living with type 2 diabetes in 2021, a figure projected to rise to 20.9 million by 2030.
Limitations Of Current Treatment Options
Current treatment guidelines recommend metformin and insulin as first-line therapies.
However, metformin fails to maintain glycaemic control in roughly half of adolescent patients, while insulin use is linked to risks such as hypoglycemia and weight gain.
The PIONEER TEENS trial represents the first clinical evaluation of an oral GLP-1 receptor agonist in this age group.
Pending regulatory approvals, oral semaglutide could become the first oral therapy in this class to show superior efficacy over placebo in pediatric patients.
Trial Design And Key Details
The 52-week study enrolled 132 participants and tested multiple dose levels of oral semaglutide against a placebo. Patients received background therapy with metformin, basal insulin, or both.
NVO Stock Price Activity: Novo Nordisk shares were down 0.05% at $39.13 during premarket trading on Thursday, according to Benzinga Pro data.
Image via Shutterstock
Recent Comments